Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arcotatug tavatecan - Innovent Biologics/Takeda

Next Previous
Drug Profile

Arcotatug tavatecan - Innovent Biologics/Takeda

Alternative Names: IBI-343; TAK-921

Latest Information Update: 27 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Developer Innovent Biologics; Ruijin Hospital
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Adenocarcinoma
  • Phase III Pancreatic cancer
  • Phase I Solid tumours
  • Clinical Phase Unknown Gastric cancer

Most Recent Events

  • 27 Aug 2026 Innovent Biologics plans a phase III trial for Pancreatic cancer (First line therapy) in China
  • 04 Jun 2026 Efficacy and adverse event data from the phase III G-HOPE-001 trial released by Innovent Biologics
  • 04 Jun 2026 Preregistration for Adenocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (IV) prior to June 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top